TGM2 and acute promyelocytic leukemia: In the NB4 WT acute promyelocytic leukemia cell line, ATRA treatment induces the maturation of cells into neutrophil granulocytes, resulting in the expression of multiple genes, including transglutaminase 2 (TG2), which is not typically expressed in healthy neutrophil granulocytes [2–4].